Liraglutide is a GLP-1 receptor agonist that helps control appetite and regulate blood sugar, supporting healthy, sustainable weight loss when combined with diet and exercise.
It is administered as a once-daily subcutaneous injection, usually in the abdomen, thigh, or upper arm, at the same time each day.
Many people see appetite reduction within the first week, with noticeable weight changes usually appearing after 4–8 weeks of consistent use.
Compounded Liraglutide is generally safe when prescribed by a healthcare provider, but it may not be suitable for individuals with certain thyroid conditions, a pancreatitis history, or severe gastrointestinal disorders.
Mild nausea, diarrhea, constipation, and headaches are common but usually temporary as the body adjusts to the medication.
